Lead Researcher Discusses Latest Pertuzumab Data in HER2+ Breast Cancer – OncLive

Posted on August 12, 2017

OncLive Lead Researcher Discusses Latest Pertuzumab Data in HER2+ Breast Cancer OncLive Results from the phase III APHINITY trial showed that adding pertuzumab (Perjeta) to standard postoperative trastuzumab (Herceptin) therapy in patients with HER2-positive early breast cancer improved the rate of recurrence overall, but had a greater …

More here:
Lead Researcher Discusses Latest Pertuzumab Data in HER2+ Breast Cancer – OncLive

Tags: , , , , , , , , , ,

Leave a Reply